Sign inJoin waitlistJoin the waitlist

Udo Rudloff

Senior Investigator · Clinical Center at the National Institutes of Health

Credentials: · · · · ·

History

Clinical Center at the National Institutes of Health
Present

Research

Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses
Science Translational Medicine · 2020 · 310 citations
Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ
Journal of Clinical Oncology · 2010 · First of 7 authors · 259 citations
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
Cancer Discovery · 2020 · 203 citations

IA
Itzhak Avital
15 papers
AS
Alexander Stojadinovic
9 papers
JM
John Mullinax
9 papers · 6 as a fellow
Russell Langan
8 papers · 8 as a resident
Humair Quadri
5 papers · 4 as a resident
Joal Beane
5 papers · 5 as a resident
Prakash Pandalai
5 papers
Rebecca Sorber
5 papers · 5 as a resident
TH
Theo Heller
5 papers
AP
Astin Powers
4 papers · 4 as a resident
CK
Christopher Koh
4 papers
Danielle Hari
4 papers · 3 as a fellow

Grants

Preclinical Drug Development in Pancreatic Cancer
National Cancer Institute · ZIA
Contact PI · $23.9M · Division of Basic Sciences - Nci

Clinical trials

Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer
Principal investigator · Terminated · Phase 1, Phase 2
National Cancer Institute (NCI)
2021–2022
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Principal investigator · Recruiting · Phase 1
National Cancer Institute (NCI)
2020–2028
M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas
Principal investigator · Terminated · Phase 1, Phase 2
National Cancer Institute (NCI)
2018–2020
Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2017–2020